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Abstract
Lung cancer is the major death-related cancer in both men and women, due to late diag-
nostic and limited treatment efficacy. The angiogenic process that is responsible for the 
support of tumor progression and metastasis represents one of the main hallmarks of 
cancer. The role of VEGF signaling in angiogenesis is well‐established, and we summa-
rize the role of semaphorins and their related receptors or hypoxia‐related factors role as 
prone of tumor microenvironment in angiogenic mechanisms. Newly, noncoding RNA 
transcripts (ncRNA) were identified to have vital functions in miscellaneous biological 
processes, including lung cancer angiogenesis. Therefore, due to their capacity to regulate 
almost all molecular pathways related with altered key genes, including those involved 
in angiogenesis and its microenvironment, ncRNAs can serve as diagnosis and prognosis 
markers or therapeutic targets. We intend to summarize the latest progress in the field of 
ncRNAs in lung cancer and their relation with hypoxia‐related factors and angiogenic 
genes, with a particular focus on ncRNAs relation to semaphorins.
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1. Introduction
1.1. Noncoding RNAs (ncRNAs)—definition, biogenesis and classification
The noncoding RNAs evolved in the last few years as important regulators of numerous 
physiological and pathological processes with increased attention regarding cancer diag-
nosis, prognosis, and therapeutics [1]. The concept known as “dark matter” defined by the 
lack of function and lack of genetic information is now long gone, being replaced by the 
 regulatory ncRNAs involved in cancer development and progression [1]. The transcription 
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of the noncoding regions produces RNA sequences that can vary in size, short, mid‐size, and 
long noncoding RNAs, and are able to influence the expression of tumor suppressor or tumor 
promoting coding genes, activity that further classifies this class of RNAs into oncogenic or 
tumor suppressor sequences [2].
The noncoding niche is rapidly expanding as new sequences are discovered and character-
ized. The ncRNAs, as their name underline, are RNAs that do not codify for proteins but 
new molecular concepts are revealed regarding the interplay between these types of RNA 
sequences and protein coding genes [3]. ncRNAs are also known as regulatory RNAs.
One of the most studied ncRNAs class is represented by microRNAs (miRNAs) that are small 
single‐stranded nucleotide sequences (18–22 nucleotide length) capable of gene regulation 
through sequence complementarity [2], being involved in all hallmarks of cancer [4]. The 
biogenesis mechanism is presented in Figure 1. The discovery of miRNAs has enabled new 
Figure 1. miRNA biogenesis mechanism. microRNAs are situated in the genome of the host as individual transcriptional 
units but also as clusters of a number of distinct microRNAs. For the first step, RNA polymerase II transcribes the target 
sequence resulting in a primary transcript named pri‐miRNAs. This unprocessed sequence is then subjected to the 
activity of RNase III‐type enzyme Drosha that transforms the pri‐miRNA sequence into a transcript of approximatively 
70 nt, pre‐miRNA. This precursor is then transferred in the cytoplasm via Exportin‐5, followed by another miRNA 
manipulation step governed by the RNase III protein Dicer, resulting in a double stranded RNA called miRNA‐miRNA 
duplex. The less stable strand is further captured by the RISC complex, association that facilitates specific gene regulation 
through complementary interactions.
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noninvasive diagnosis methods and also has conducted towards the development of more 
targeted therapeutics alternatives in a large number of cancers and other pathological states 
[4, 5]. Despite numerous discoveries in the ncRNA field, the two main noncoding fronts in 
cancer are still represented by microRNAs and the more recent characterized long noncod-
ing RNAs (lncRNAs) [6]. As the technology advances, these last sequences are increasingly 
mentioned in pathological contexts, where differential expression levels are associated with 
malignant states and other diseases [6]. Despite the associations between lncRNAs expression 
patterns and different types of cancers, there are still many unknowns regarding the complex 
mechanism of action.
MiRNAs revolution has stimulated the investigation of other types of small ncRNAs such as 
small interfering RNAs (siRNAs), and Piwi‐interacting RNAs (piRNAs) [3, 7, 8]. These last 
two types of molecules are similar to miRNAs in length and function, where siRNAs medi-
ate posttranscriptional inhibitory processes and piRNAs act particularly on transposable ele-
ments and are capable of forming complexes with Piwi proteins [7, 8]. piRNAs transcribed 
from kiwi clusters together with Piwi proteins are capable of transposon modulation through 
interruption of the specific transcript that will be no longer able to exercise their specific activ-
ity. Other types of ncRNAs, circularRNA (ciRNA) are formed through base pairing of intronic 
repeats that ends up with a complete circular fragment that is able to act as a miRNA sponge 
through complementary interactions [3, 9].
Supplementing the complex regulatory networks of miRNAs, ciRNAs have recently emerged 
as new cancer modeling tools through miRNA targeting, escaping from the initial character-
ization as transcriptional “noise” [9, 10]. These types of transcripts are ubiquitous present in 
eukaryotic cells and competitively bind microRNAs sequences, functioning like an inhibitory 
sponge; process that could attribute a significant therapeutic potential to these circular frag-
ments [9, 10, 11, 12]. In this sense, specific microRNAs are eliminated from the regulatory 
networks, influencing the expression scheme of target genes. Competitive endogenous RNA 
(ceRNA) describes a new mechanism of gene regulation, being involved in physiological and 
pathological processes [13].
The traditional concept that RNA molecules are just intermediary sequences between 
DNA and proteins is now replaced with more advanced molecular data, where short‐ 
and long‐noncoding sequences play a key role in normal development and disease pro-
gression [14]. SiRNAs and miRNAs are similar in length, approximatively 22 nucleotides, 
and are both processed by Dicer through cleavage. SiRNAs are derived from complemen-
tary dsRNA duplexes, where miRNAs originate from imperfect RNA hairpins from short 
introns or long transcripts [15–18]. Both small noncoding types of sequences associate with 
Argonaute proteins in order to manipulate gene expression (generally through 3′UTRs) 
[19], although siRNAs are also involved in viral defense and transposon regulation. piR-
NAs are the longest fragments from the small RNAs group, having approximatively 26–30 
in length. This class associates with PIWI‐clade Argonaute proteins in order to guide trans-
poson activity and chromatin status [15, 17]. Long noncoding RNA group consist in all 
RNA sequences that are not responsible for protein generation and their length exceed 
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200 nucleotides, being further grouped in concordance with their genomic localization: 
intronic, intergenic, sense, and antisense ncRNAs to host gene locus [6, 20]. Biogenesis 
of lncRNAs is very similar with the processing activity of mRNAs molecule, being tran-
scribed by RNA Pol II and also being subjected to the same epigenetic modifications and 
splicing signals. The functional roles of lncRNAs are more extended than in the case of 
small ncRNAs, a significant part being still incompletely understood. Briefly, this type of 
sequences is not so well conserved as miRNAs and also can control gene activity at differ-
ent levels in a more complex scheme [2, 6, 16].
2. Lung cancer—molecular classification and survival rates
Lung cancer occupies the first place regarding the mortality rates from the oncological field, 
being characterized by an aggressive profile that ends with numerous deadly metastatic 
sites. One of the main reasons for the high mortality rates consists in the late diagnosis [21]. 
According to the characteristics of the cancer cells, this malignancy presents itself in two 
major forms, one being small-cell lung cancer (SCLC), and the other being named non-small-cell 
lung cancer (NSCLC) according to the histological classification and another rare subtype, lung 
carcinoid tumor (LCT) [22, 23]. NSCLC ranks as the number one diagnosed type of lung cancer 
in the oncological field, being further divided into three histologic types: squamous cell carci-
noma, large-cell carcinoma, and adenocarcinoma. Adenocarcinomas represent the most common 
subtype of NSCLC, with an incidence of 35–40% from all lung cancer cases, being the most 
lethal type of cancer in male population, and the second in women. This type of pulmonary 
malignancy frequently presents distant metastases and pleural effusions. Between a quarter 
and 30% of all lung cancer cases belong to the squamous cell carcinoma category. These par-
ticular tumors are mostly located in the central areas of the lungs, and were shown to be con-
nected to tobacco smoking [24]. Lung carcinoid tumors are very rare and represent about 5% 
of the lung cancers which grows very slowly and are rarely associated with metastasis [25]. 
Despite the frequency drop, pulmonary tumors remain the major cause of death and morbid-
ity around the world, being very aggressive and refractory to standard oncologic therapy [26], 
due to the late diagnostic [27].
Environmental and occupational exposure to different agents and an individual's suscepti-
bility for these agents were associated with a risk of lung cancer in approximately 9–15% of 
cases. The cigarette smoke is the primary risk factor for the development of lung cancer and is 
estimated to be responsible for approximately 90% of all lung cancers [24], followed by asbes-
tos [28], and radon [27]. More than 300 harmful substances with 40 known potent carcinogens 
were discovered in tobacco smoke.
The classical therapeutic strategies like surgery and chemotherapy or radiation fail to accom-
plish their purpose in advanced pathological states. In the case of patients diagnosed early 
in the disease, the chances of survival are more promising, being observed a partial response 
to drugs based on platinum. However, even in this case, the final outcome is not necessary 
a positive one due to acquisition of treatment resistance. According to National Cancer 
Institute, survival rates for early stages of NSCLC are extremely low compared to other types 
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of cancer, where the rate for the late stages of the same malignancy can reach even 1%: the 
5 years survival rate for stage IA is approximately 49%, 45% for stage IB, 30% for stage IIA 
and 31% for IIB. The next stages, IIIA and IIIB, are associated with even more dramatically 
numbers, 14% and 5% respectively (Figure 2). For the case of metastatic lung cancer, where 
the tumor has spread within different body sites, the survival rates are extremely low (1%) 
[29, 30]. Therefore, a critical part of lung cancer management is represented by the discovery 
of specific molecular carcinogenic pathways in order to precisely target key molecules that are 
responsible for tumor development and avoid treatment resistance. ncRNAs study represents 
an important research direction for achieving these goals.
3. Angiogenesis—beyond hallmarks of lung cancer
Nowadays, the cancer hallmarks are at the center of carcinogenesis: prolonged prolifera-
tion signals, escaping of growth inhibitors, apoptosis inhibition, indefinite replicative poten-
tial, vascular network development (angiogenesis) and activation of cell invasion, and thus 
metastasis (Figure 3) [31]. Although all of these hallmarks represent key elements without 
which tumorigenesis could not more or less advance, angiogenesis surpasses this listing of 
malignant processes: without the ability to receive oxygen and nutrients and evacuate waste 
products, the spreading of the tumor is naturally restricted. Moreover, the vessel network is 
one of the invasion routes used by transformed mesenchymal cell in order to evade from the 
original carcinogenic site and invade other tissues [31]. All these features stand at the base of 
the therapeutic concept, where angiogenesis is one of the main signaling pathway targeted 
in the treatment of cancer patients, including individuals with lung cancer. Inhibition of this 
malignant progression pathway through exogenous administration of targeted agents in the 
form of ncRNAs/anti‐ncRNAs will enable the proper management of tumor spreading and 
will serve as a feasible therapeutic strategy for lung cancer [33].
The most promising proangiogenic target in lung cancer is VEGF (vascular endothelial 
growth factor), more precisely the interaction of VEGF with the transmembrane  receptors 
or receptors downstream the signaling pathways. However, prolonged exposure to 
VEGF/VEGFR inhibitors may force tumor cells to find alternative pathways for vascular 
Figure 2. The overall survival rates associated with different lung cancer subtypes (NSCLC, SCLC) and the 5‐year 
survival rate based on lung cancer stages.
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 development [34]. Additionally, some other angiogenic pathways have been explored with 
the same purpose, where FGFRs (fibroblast growth factor receptors), angiopoietin, PDGFRs 
(platelet‐derived growth factor receptors), and, in the last few years, semaphorins and the 
related receptors captured the attention [32, 34]. The metastatic cascade, a multievent pro-
cess that leads to the spreading of the tumor cells to numerous sites in the organism and 
causes death, represents the main challenge in cancer treatment and angiogenesis plays a 
major role in this progression [35].
3.1. Implication of ncRNAs in regulation of lung cancer angiogenesis
As a result of the limited success of the classical antiangiogenic therapies targeting VEGF 
and its related receptors [35, 36], researchers have deepened their knowledge by analyzing 
the expression of ncRNAs sequences in this pathology (Figure 4) [37, 38]. The mechanism of 
lung cancer angiogenesis is far from being completely deciphered and implicit the process of 
therapeutic inhibition via ncRNAs remains to be further investigated. Targeting ncRNAs will 
enable a more precise treatment and will avoid compensatory mechanisms retrieved in lung 
cancer [2, 37, 38].
Figure 3. Lung cancer hallmarks with focus on angiogenesis.
Physiologic and Pathologic Angiogenesis - Signaling Mechanisms and Targeted Therapy256
3.2. miRNAs related to lung cancer angiogenesis
Among all types of ncRNAs, miRNAs molecules are the most intensive studied in what 
regards novel cancer therapies. Although the majority of the studies are concentrated on 
oncogenic miRNA inhibition via exogenous delivery of complementary (antisense) sequences 
through different vectors, it seems that another therapeutic alternative consists in miRNA 
replacement. This last type of targeted treatment may be even more effective due to the fact 
that the predominant pathological model consists more in dowregulated tumor suppressor 
sequences than overexpressed oncogenic genes [5, 21, 39].
Until this moment, several miRNA patterns involved in different lung cancer processes such 
as cell proliferation, resistance to therapy, invasion, metastasis, and angiogenesis have been 
identified. We will focus on some important miRNAs that presented the most aberrant expres-
sion related to lung cancer angiogenesis (Tables 1 and 2).
Figure 4. Evolution of vascular network within lung cancer. Malignant cells lacking nutrients and oxygen enter 
in hypoxic stress, state that promotes the signaling pathways related to angiogenesis in order to sustain cell 
proliferation. The same process is present at the metastatic sites, where mesenchymal cells that went through 
epithelial to mesenchymal transition are establishing new malignant formations. The complex malignant scheme is 
strictly regulated by noncoding RNAs (miRNAs and lncRNAs). Red ‐ overexpressed ncRNAs; Green‐ downregulated 
ncRNAs.
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No. Name Location Length 
(nucleotides)
Expression 
level
Target 
gene
Activity Possible role in lung 
cancer angiogenesis
Clinical potential References
1 miR‐27b 9q22.32 22 ▼ Sp1 Possible key miRNA 
regarding the 
development of lung 
cancer; ectopic expression 
reduced the cell growth 
and invasion
Sp1, a target gene of miR‐27b, was 
associated with the angiogenic 
phenotype in gastric cancer, with 
key roles in the manipulation of this 
process; patients with high levels of 
Sp1 presented a more vascularized 
phenotype
Therapeutic 
target
[40, 41]
2 miR‐126 9q34.3 22 ▼ VEGF‐A Low expression of this 
miRNA is associated with 
high vascular density in 
NSCLC; this data were 
also observed in vitro
Due to direct targeting of miR‐126 
on VEGF‐A, overexpression of this 
miRNA could be suitable for anti‐
angiogenic therapies
Therapeutic 
target and also 
prognosis tool
[42]
3 miR‐130a 11q12.1 21 ▼ MET miR‐130a  downregulates 
the expression levels of 
two oncogenic miRNAs, 
miR‐221 and miR‐222; 
MET suppression
MET represents a key factor 
for vascular development and 
miR‐221/222 cluster could also play 
an important role in angiogenesis 
due to the direct down regulation of 
TIMP3, an inhibitor of MET; miR‐130 
is able to reduce the levels of both 
this systems
Important 
therapeutic 
potential
[43, 44]
4 miR‐15/16 13q14.3 – ▼ BCL‐2 
and 
BCL‐XL
MiR‐15/16 cluster was 
found as downregulated 
in NSCLCs; miR‐15 
directly targets BCL‐2 
and BCL‐XL
BCL‐2 has a suppressive action on 
VEGF and TP in lung cancer, both 
strongly implicated in angiogenesis 
development
Contradictory 
results; further 
studies needed
[45–47]
5 miR‐378 5q32 21 ▼ VEGF Inhibition of lung cancer 
angiogenesis through 
VEGF targeting
Regulator of a central element in 
lung cancer angiogenesis
In vivo 
demonstrated 
therapeutic 
target
[48, 49]
6 miR‐296 20q13.32 21 ▼ CX3CR1, 
PLK1
Tumor suppressor role in 
lung cancer development 
targeting chemosensitivity 
and cell viability
MIR‐296 has been associated with 
angiogenesis
Potential 
therapeutic 
target
[50–52]
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No. Name Location Length 
(nucleotides)
Expression 
level
Target 
gene
Activity Possible role in lung 
cancer angiogenesis
Clinical potential References
7 miR‐128 2q21.3 23 ▼ VEGF‐A, 
VEGF‐C, 
VEGF‐2, 
VEGF‐3
In vitro and in vivo 
overexpression 
of miR‐128 led to 
significant suppression 
of angiogenesis due to 
down regulation of the 
target genes; furthermore 
miR‐128 expression 
is correlated with the 
development stages of 
lung cancer
Current data shows that miR‐128 
could be used effectively as 
therapeutic target or prognostic tool
Therapeutic 
target for 
enhanced 
expression and 
prognosis  tool
[53]
8 miR‐497 17p13.1 20 ▼ HDGF Ectopic expression 
of this sequence in 
an animal model 
demonstrated positive 
effects through inhibition 
of cell proliferation and 
angiogenesis
Experimental data shows that 
miR‐497 could be used with success 
as an antiangiogenic agent for lung 
cancer
Therapeutic 
target
[54]
9 let-7b 22q13.31 21 ▼ RAS Lung cancer tumors tissue 
revealed a downregulated 
pattern and was 
associated with increased 
vascular density
The collected data suggest a possible 
role for miR‐7b as antiangiogenic tool 
in the moment of ectopic expression
Prognosis and 
therapeutic tool
[55]
10 miR‐145 5q32 22 ▼ SMAD3 Implicated in EMT and 
invasion
Enhancement of this miR expression 
could serve as a therapeutic strategy 
for lung cancer
Possible 
therapeutic 
target
[56]
11 miR‐205 1q32.2 20 ▼ VEGF Implicated in EMT and 
invasion
Enhancement of this miR expression 
could serve as a therapeutic strategy 
for lung cancer
Possible 
therapeutic 
target
[57]
Table 1. The main tumor suppressor altered miRNAs implicated in lung cancer angiogenesis.
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No Name Location Length 
(nucleotides)
Expression 
level
Target gene Activity Possible role in lung cancer 
angiogenesis
Clinical 
potential
References
1 miR‐221
miR‐222
Xp11.3 23 ▲ PTEN, 
TIMP3
Highly expressed in lung 
cancer cells; promotes 
invasion and migration
miR‐221/222 cluster could have 
a role in angiogenesis promotion 
through down regulation of 
TIMP3, an inhibitor of MET, an 
angiogenesis promoter
Therapeutic 
target and 
patients 
stratification 
toll
[58]
PUMA Co‐modulation of the 
two miRNAs on PUMA 
promotes cell proliferation 
and inhibits apoptosis [59]
2 miR‐222 Xp11.3 23 ▲ P27 Increased miR‐221/222 
expression promotes 
H460 cells viability and 
proliferation
Considering the possible in 
vivo role of p27, where the 
overexpression of this gene 
impaired angiogenesis, miR‐222 
that inhibits the expression of p27 
could become a potent therapeutic 
target regarding antiangiogenic 
strategies
Therapeutic 
target for 
inhibition
[60, 61]
3 miR‐210 11p15.5 22 ▲ Significantly up‐regulated 
in lung cancer tissues and 
associated with angiogenic 
potential in other types of 
cancers 
Due to the regulation by HIF‐1 
involved in hypoxia (event 
that triggers angiogenesis 
development), miR‐210 could also 
become a therapeutic target
Still limited 
data
[62, 63]
4 miR‐155 21q21.3 22 ▲/▼ FGF2 MIR‐155 expression is 
correlated with FGF2 levels, 
an important molecule for 
lung cancer angiogenesis. 
Also, mimR‐155 was 
correlated with VEGF‐A in 
the N+ subgroup of NSCLC
Several studies have investigated 
the role of this miR in angiogenesis
Prognosis 
and 
therapeutic 
tool
[64, 65]
FOXO3A, 
SOCS1, 
SOCS6, 
and PTEN
Hypoxia promotes miR‐
155 increased expression 
concomitant with the 
downregulation of 
FOXO3A target
[65, 66]
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No Name Location Length 
(nucleotides)
Expression 
level
Target gene Activity Possible role in lung cancer 
angiogenesis
Clinical 
potential
References
5 miR‐21 17q23.1 21 ▲ PTEN, 
SOCS1, 
and, 
SOCS6
After antiangiogenic 
therapy this miR 
was observed as 
downregulated 
Possible role in lung cancer 
angiogenesis observed after 
the post‐antiangiogenic down 
regulation
Possible 
therapeutic 
target
[66]
6 miR‐182 7q32.2 23 ▲ FRS2 miR‐182 directly targets 
FRS2 in lung cancer, 
gene that represents 
a key molecule for 
NSLC progression and 
antigenesis
N/A Therapeutic 
and 
diagnosis 
tool
[67]
7 miR‐106a Xq26.2 22 ▲ – Augmented expression of 
miR‐106 in NSCLC was 
reported in several studies
Previously associated with hypoxia 
progression in colon and breast 
cancer that could enable a possible 
role in lung cancer hypoxia/
angiogenesis
Possible 
therapeutic 
target
[67–69]
Table 2. The main oncogenic miRNAs involved in lung cancer angiogenesis.
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3.3. LncRNAs related to lung cancer angiogenesis
The number of lncRNAs has significantly increased due to the progresses offered by sequenc-
ing methods in genomic research. Long noncoding transcripts act as gene regulators via a 
wide range of mechanism [70], those related to lung cancer being summarized in Table 3. 
The first long noncoding sequence associated with lung cancer was MALAT1 that through 
increased expression and gene targeting (caspase‐8, caspase‐3, BCL‐XL, BCL‐2, and BAX) 
promotes the proliferation and invasiveness of cancer cells. Recently it was emphasized to 
target SLUG gene via a competitively “sponging” miR‐204 [71]. Following this initial lncRNA, 
a significant list of lncRNA was associated with lung cancer progression or inhibition through 
modulation of key mechanisms involved in the hallmarks of lung pathology. The regulatory 
process is complex, lncRNAs being able to escort chromatin modifying enzymes to target loci 
within the genome, to bind the promoter of genes and modify the transcription process, to be 
processed into miRNAs and further act as short noncoding transcripts, and finally to modify 
the stability of specific mRNAs through direct binding [70].
Recent evidences suggested the role of PANDAR in lung cancer cell proliferation through p53/
PANDAR/NF‐YA/Bcl‐2 axis [72]. Another lncRNA positively regulated by p53 is TUG1, whose 
downregulation is associated with increased cell proliferation and poor survival rate in lung 
cancer patients [73]. Also, considering the antiangiogenetic role of the p53 gene and the posi-
tive correlation between the two sequences, there is a possible role for TUG1 in angiogenesis 
suppression, however further investigations are necessary. HOTTIP is a long noncoding tran-
script that is associated with tumor growth [74], process that involves the formation of new 
blood vessel network, fact that could transform HOTTIP into a new target for antiangiogenetic 
therapies. MVIH is associated with microvascular invasion in HCC, being upregulated in this 
type of cancer with an increased oncogenic potential. Further studies have investigated the 
possible role of the same lncRNA in lung cancer and the results were increasingly similar with 
the previous pathology, MVIH representing a biomarker for poor prognosis and associated 
tumor cell proliferation [75]. There are also other lncRNAs with tumor suppressor or tumor 
promoting roles in lung cancer malignancies, like MEG3 (tumor suppressor), ANRIL, and 
AK001796 (oncogenic role) that are involved in cell proliferation and cell viability, processes 
that go hand in hand with the angiogenetic transformation [76–78]. lnRNA BC087858 is overex-
pressed in NSCLC and was demonstrated to be connected with drug resistance via EGFR‐TKIs 
axis [80]. MEG3 was proved to be downregulated in tumoral tissue, and directly related with 
high tumoral stage. Preclinical studies demonstrated a reduced proliferation rate in the case 
of MEG3 overexpression, by targeting MDM2 and p53 proteins. MEG3 is presented not only 
as prognostic marker but also as important therapeutic target [76]. ANRIL is overexpressed in 
lung cancer tissue, being correlated with tumor-node-metastasis stages and tumor size, but 
until now there are not presented data with a direct connection with  angiogenesis [78].
3.4. Ultraconserved regions (UCRs)
Ultraconserved regions (UCRs) are genome sequences longer than 200 bp and, as the 
name suggests, are conserved within humans, rats, and mouse, preserving their nucleotide 
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lncRNA Target gene Biological role Reference
TUG1 PRC2 Tumor suppressor lncRNA regulated by p53, gene 
that promotes the expression of TUG1
[73]
MEG3      MDM and p53 Tumor suppressor role through cell proliferation 
reduction and increased survival. P53 expression 
is frequently correlated with the expression 
of the MEG3, with possible cumulative role in 
angiogenesis suppression
[76]
MALAT1 SLUG Promoter of EMT and metastasis, via miR‐204 [71]
PANDAR NF‐YA Inhibits tumor cell proliferation in the moment of 
overexpression through p53/PANDAR/NF‐YA/
Bcl‐2 axis
[72]
LUADT1 p27 Oncogenic role through promotion of cell 
proliferation; knockdown of the target gene 
significantly contribute to the reduced tumor size 
by inhibition of cell expansion
[79]
HOTTIP Cdc25C Promotes tumor growth and is overexpressed in 
lung cancers
[74]
ANRIL KLF2 and p21 Oncogenic role; knockdown of this lncRNA reduced 
proliferation and increased apoptosis
[78]
MEG3 MDM and p53 Tumor suppressor role exercised through cell 
proliferation reduction and increased survival. 
P53 expression is frequently correlated with the 
expression of the MEG3, with possible cumulative 
role in angiogenesis suppression
[76]
AK001796 BIRC5/TPDF2/CDC/GA Oncogenic role; involved in maintaining the tumor 
cell viability through complex mechanisms
[77]
MVIH MMP‐2 and MMP‐9 Overexpressed in lung malignancies, being 
associated with increased cell proliferation and poor 
prognosis; previously recognized as angiogenesis 
promoter in HCCs
[75]
BC087858 EGFR‐TKIs Promotes cells invasion and induces drug resistance 
to EGFR‐TKIs by activating PI3K/AKT and MEK/
ERK pathways and EMT via up‐regulating ZEB1 
and Snail
[80]
ZXF1 c‐Myc LncRNA ZXF1overexpression was connected with 
a relatively poor prognosis; Knockdown by siRNA 
has no effect on cell proliferation, but  decreased the 
migration and invasion of lung cancer cells
[81, 82]
LINC01207 EZH2 Cancer initiation and progression [83]
LincRNA‐p21 p53 and HIF1A Regulation of TP53‐dependent apoptosis and 
Warburg effect and angiogenesis
[84]
Table 3. The main lncRNAs involved in lung cancer angiogenesis and possible therapeutic targets for inhibiting lung 
cancers.
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 succession during the evolution [85, 86]. Until this moment there are a number of 481 con-
served sequences, a part of them being situated at sensitive sites regarding cancer susceptibil-
ity and are further transcribed (T‐UCR) into pathological expression patterns. Considering 
this recent discovery, it has been postulated that the differential expression pattern could 
serve as stratification tool in the oncology domain, being able to differentiate between human 
cancers and possible between molecular subtypes of carcinomas [85, 86].
The exact mechanism that leads to aberrant expression of T‐UCR is not fully deciphered, 
although it is thought that the primary regulation models are represented by miRNAs interac-
tions and epigenetic modifications in CpG islands hypermethylation [85].
Calin et. al. were the first to discover the T‐UCR spectrum in malignant cells compared with 
healthy ones and found significant differences between the two states [85]. So far, molecular 
analysis have revealed different T‐UCR signatures in a number of carcinomas, including pros-
tate, hepatocellular, and colorectal cancer, as well as in chronic lymphocytic leukemia and 
neuroblastoma. Presently was observed upregulation of several T‐UCRs and demonstrated 
by multiple investigations to be related with increased risks for tumour occurrence and a high 
metastatic rate. Therefore, the main investigation area is focused on integration of synthetic 
antisense oligonucleotides (ASOs) to inhibit T‐UCR functions [85]. In lung cancer, an impor-
tant number of T‐UCRs need to be characterized and then used for developing novel thera-
pies. In spite of the interest on the T‐UCR, there are only few investigations on T‐UCR therapy.
4. ncRNAs related to hypoxia in lung cancer
Hypoxia is a preangiogenetic process driven by specific gene modifications, alterations that 
are able to induce the installation of the mesenchymal phenotype through epithelial to mes-
enchymal transition (EMT), acquisition of drug and radiation resistance, and propagation of 
lung cancer stem cells [87, 88]. Compared to other cancers, lung malignancy is severely sus-
tained by the installation of hypoxia through complex interactions between specific molecules 
(HIF1α and miRNAs or other ncRNAs, as displayed in Tables 4 and 5) and establishment of 
noncoding regulatory networks related to connection with the cell cycle regulation, apoptosis 
or autophagy [88].
In terms of lung cancer hypoxia, miRNAs play a pivotal role through the ability to orchestrate 
extensive signaling networks involved in this carcinogenic step. MiR‐200 family has been 
extensively characterized in numerous malignant scenarios and miR‐200b member seems 
to have a role that could be exploited in the context of the clinical area regarding hypoxia 
induced EMT where cells acquire motility characteristic and are able to invade secondary 
sites within the organism promoting lung cancer metastasis [89]. Reinforced expression of the 
tumor suppressor miRNAs inhibited EMT through regulation of key genes involved in this 
pathway [88]. Another possible therapeutic target is represented by miR‐21, that is elevated 
in NSCLC‐derived cells grown under hypoxic conditions [90]. Hypoxic conditions also trig-
gered miR‐155 overexpression and downregulation of FOXO3A target gene, and protects 
lung cancer cells to irradiation, elucidating a possible course of treatment through inhibition 
of miR‐155 combined with radiotherapy [65].
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Type of 
miRNA
Expression 
level
Name Target 
gene
miRNA role in lung cancer 
hypoxia
Possible clinical role 
of miRNAs in lung 
cancer
References
Tumor 
suppressor 
miRNAs
▼ miR‐200b – Hypoxia‐induced EMT in 
lung cancer, influencing 
the activity of key genes 
involved in mesenchymal 
transition miR‐200 mimic 
blocks hypoxia‐induced 
EMT
Novel therapeutic 
strategy via Nobiletin 
delivery
[89]
▼ miR‐210 – Regulate cellular response 
under hypoxic conditions 
High levels connected 
with a positive outcome in 
NSCLC patients
Biomarker for 
prognosis and patient 
stratification
[63, 91]
▼ miR‐18a HIF‐1α Connected with lung 
metastasis of breast cancer 
cells ability to decrease the 
hypoxic stress in vitro and 
reduce cell invasiveness
Possible prognosis 
factor of lung 
metastasis in breast 
cancer
[92]
▼ miR‐199a HIF1α Inhibition of cancer 
cell hypoxia induced 
proliferation in NSCLC 
cells
Possible prognosis 
factor
[93]
Oncogenic 
miRNAs
▲ miR‐21 – NSCLC derived cell lines 
grown under hypoxic 
condition showed 
an elevated miR‐21 
expression; modulates 
radiation resistance via 
hypoxic mechanism
Possible therapeutic 
and prognosis role
[87, 90]
▲ miR‐339 RASSF1, 
ERBB4, 
KRAS
Activity correlated with 
the process of response to 
hypoxia
Possible target for 
therapeutic strategies
[94]
▲ miR‐155 FOXO3A Correlates with poor 
prognosis and protects 
hypoxic lung cancer 
cells to irradiation and 
conversely
Therapeutic potential 
for radio sensitization 
of hypoxic lung 
cancer cells
[65]
▲ miR‐17‐92 
cluster
HIF1α Downregulation of HIF1α 
does not affect the cellular 
adaptation to hypoxia
Possible prognosis 
factor
[95]
▲ miR‐494 PTEN Promotes angiogenesis 
through direct targeting 
of PTEN and activation 
of Akt/eNOS pathway; 
expression is induced 
during hypoxia
Possible prognosis 
and therapeutic tool
[96]
Table 4. Tumor suppressor and oncogenic miRNAs involved in lung cancer hypoxia with possible roles in diagnosis, 
prognosis, and therapy.
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Hypoxia management has led to reduced angiogenesis and thus obtuse the malignant cell 
proliferation and survival due to deprivation of nutrients and oxygen via various molecules 
including the noncoding transcripts represented by miRNAs and lncRNAs. Multiple target-
ing through ncRNAs that are able to influence the fate of the hypoxic microenvironment will 
bring new insights into the pathogenesis of lung cancer, permitting the development of new 
clinical tools for cancer management, improving the concerning survival rate of this pathol-
ogy. The list of miRNAs and lncRNAs implicated in the vascular invasion of the pulmonary 
malignancy is presented in Tables 4 and 5.
Type of 
lncRNA
Expression 
level
Name Target gene lncRNA role 
in lung cancer 
hypoxia
Possible clinical 
role of lncRNAs in 
lung cancer
References
Tumor 
supressor 
lncRNAs
▼ lncRNA‐LET 
(Low expression 
in tumor)
HIHD3; 
hypoxia‐
induced 
histone 
deacetylase 3
Squamous‐cell 
lung carcinomas 
downregulated by 
HIHD3 promotes 
hypoxia‐induced 
cancer cell 
invasion
New methods 
for therapeutic 
intervention
[97]
▼ GAS5‐AS1 – Downregulation 
of GAS5‐AS1 
contributes to 
hypoxia tumor 
metastasis in non-
small cell lung 
cancer
Prognosis and 
therapeutic 
marker
[98]
▼ LincRNA‐p21 TP53 and 
HIF‐1α
Target angiogenic 
mechanisms
Prognosis marker [84]
Oncogenic 
lncRNAs
▲ HOTAIR (HOX 
transcript 
antisense 
intergenic RNA)
HIF‐1α HOTAIR is 
upregulated 
in hypoxic 
conditions and 
is a direct target 
of HIF‐1α; 
Promotion 
of cancer cell 
proliferation and 
ability to migrate 
and invade other 
sites 
Novel therapeutic 
target
[99, 100]
▲ H19 HIF‐1α Possess oncogenic 
properties 
triggered by 
hypoxic stress 
Correlates  with 
p53 tumor 
suppressor status
Prognosis/
Diagnosis marker
[101]
Table 5. LncRNAs involved in lung cancer hypoxia with possible roles in diagnosis, prognosis, and therapy.
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LncRNAs have recently emerged as important prognosis and therapeutic tolls in different 
malignancies and even for specific carcinogenic processes as lung cancer hypoxia. One of the 
main studied lncRNAs is HOTAIR, pathological expressed in numerous malignant scenarios, 
being associated with tumor promoting roles and a negative outcome in oncological patients. 
It was demonstrated that this lncRNA is a direct target for HIF‐1α that act as an enhancer of 
expression and contribute together to the securitization of hypoxia followed by cell prolif-
eration, migration, and metastasis. This information could transform HOTAIR in a possible 
therapeutic target under hypoxic conditions for NSCLC, that is limited in what regards the 
therapeutic options [99, 100]. Another newly discovered lncRNAs in lung cancer hypoxia 
that is lncRNA‐LET targeted by HIHDR. The interaction between these two molecules ends 
with reduction of histone acetylation at the promoter region of the noncoding transcripts and 
thus decreased expression. Moreover, the downregulation process secures the expression of 
nuclear factor 90 proteins, a key element for cell migration induced by hypoxia. This data sug-
gest that lncRNA‐LET can be used as a clinical tool against cancer promotion [97].
LincRNA‐p21 impacts prognosis in resected nonsmall‐cell lung cancer patients through 
angiogenesis regulation. LincRNA‐p21 was proved to be activated by TP53 and HIF1A [84]. 
It was proved to target the apoptosis pathway via regulation by p53 and the Warburg effect. 
LincRNA‐p21 is downregulated in tumor tissue, and has effect on the lung cancer patients via 
angiogenesis regulation [84].
Other important ncRNA structures with a significant role in the development of novel molec-
ular therapies are represented by PIWI‐interacting RNAs (piRNAs). piRNAs are recognized 
to be involved in transposon silencing and gene expression during development and the com-
plete role on the somatic cells remains to be deciphered [8]. In a recent paper were empha-
ses a different piRNASs expression profiles between normal bronchial epithelial cells and 
lung cancer cells. The most downregulated piRNAs in lung cancer cells was piRNA‐like‐163 
(piR‐L‐163) having as direct target the phosphorylated ERM (p‐ERM) [102]. S100A4‐small 
interfering RNA (S100A4‐siRNA) was proved to activate the apoptosis and increase the radio-
sensitivity of A549 lung cells. S100A4 may promote A549 cell proliferation but also invasion, 
and metastasis by regulating the expression of E‐cadherin and p53 protein [103].
5. ncRNAs targeting semaphorines and its related receptors in lung cancer
Semaphorins are guidance molecules which were characterized initially as directing ele-
ments for axon outgrowth; however advances in genomic and translational medicine 
revealed a more complex role for these proteins, being involved in cell migration, vascular 
network, and tissue development [32, 104]. Considering their vital role in physiological 
processes is not surprising that these guidance proteins are also involved in similar patho-
logical processes especially from the oncologic area, where they exercise the same func-
tions, but in a negative manner [32]. Therefore, semaphorins are implicated in carcinogenic 
establishment, metastasis, and especially angiogenesis in numerous cancers, including lung 
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cancer. Regarding their role in angiogenesis, the family of semaphorins is divided into two 
main pathological classes: tumor suppressors inhibiting the angiogenic process and onco-
genes through promotion of vascular invasion. Therefore, loss of expression in the case of 
antiangiogenic semaphorins and/or increased expression pattern for the procarcinogenic 
ones translates into sustaining of the malignant cells [106]. Immediately after the estab-
lishment of their newly discovered role, in vitro and in vivo studies confirmed the ability 
of semaphorins to serve as therapeutic targets in the form of suppression or enhancement 
[32]. Despite the fact that their role in pulmonary malignant processes is quite extensively 
studied, little is known about the ncRNAs regulatory action on the expression pattern of 
semaphorins. Deciphering the regulatory noncoding sequence panel for these proteins will 
enable a more advanced and specific molecular management of lung cancer, especially in 
angiogenesis that has a vital role regarding the maintenance of tumor cells integrity and 
proliferation.
The process of angiogenesis, can also occur through semaphorin receptors, neuropilins, and 
plexins (Figure 5). In the case of neuropilins, we encounter a multiple ligation system, this 
membrane proteins being able to bind both class‐3 semaphorins, VEGF and growth factors. 
Also, this type of receptors that are essential to proper vascular development during organ-
ism development are generally mutated in lung cancer. On the other hand, in vivo suppres-
sion of neuropilins led to improper vascular network.
Among the first studies that elucidated the role of neuropilins in vascular development is the 
research where the authors observed that overexpressing of Nrp1 was lethal for embryos due 
to extensive vascular defects like overdevelopment of blood vessel network and deformed 
hearts [107]. This discovery paved the way for further research in the area of cancer manage-
ment with focus on targeted therapy. Therefore, it has been proven that a combined form 
of therapy represented by neuropilins inhibitors (semaphorin, anti‐NRP, soluble NRP ‐ B 
domain, and VEGF mimetics) administrated concomitant with anti‐VEGF signaling mole-
cules (kinase inhibitors, anti‐VEGF, anti‐VEGFR‐2, and soluble VEGFR for VEGF) is more 
efficient than the classical antiangiogenic therapeutic strategy targeted towards VEGF alone 
[104]. Research studies demonstrated a role for NRP1 and NRP2 in lung cancer progression 
and angiogenesis where these two molecules were observed as normally expressed in bron-
chial basal cells, and as it progressed in the severity of the cell lesions, the level of neuropilins 
increased significantly, concomitant with VEGF expression [104]. NRP1 has been previously 
associated with cancer angiogenesis: overexpression of NRP1 in AT2.1 cells (in vitro model of 
prostate cancer) resulted in advanced vascular density, cell proliferation, and also inhibited 
apoptosis [108]; rat estrogen‐induced pituitary tumors presented increased levels of NRP1, 
level that was also correlated in a positive manner with the aggressiveness of angiogenesis 
development [109].
The competitive binding of class‐3 semaphorins and VEGF that in physiological conditions 
leads to the proper development of the vascular platform is changed during malignant sce-
narios where proangiogenic VEGF takes the lead due to mutations in the structure of the bind-
ing domain that decreases the complementarity with semaphorins or enhances the expression 
of receptors. Therefore, an alternative therapeutic pathway could be represented by the 
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 modulation of neuropilins (NRPs) expression. Furthermore, the specific malignant expres-
sion is most likely influenced by other molecules such as miRNAs and lncRNAs (Table 6).
Lung cancer therapies focused on semaphorins and their receptors are still an insufficiently 
explored domain that could hold great promises regarding the inhibition of cancer spread-
ing. Considering the competitive binding between class‐3 semaphorins and VEGF in vascular 
development, antiangiogenic strategies as antibodies for VEGF or NRP inhibition, soluble 
NRP or NRP blocking peptides have been tested with effective results [104, 106]. A more 
recent treatment compromising both VEGF and SEMA3A inhibitors have been applied in vitro 
and in vivo for colon cancer [105]. Another type of action could be represented by the induced 
internalization of the neuropilins through administration of dextran sulfate and fucoidan 
that significantly decreased the number of endothelial surface receptors, including VEGFR 
[131]. Although anti‐VEGF molecules are well‐known as efficient angiogenesis inhibitors, 
combining the modulation of VEGF/VEGFR with SEMA/NRP may hold significant clinical 
usage. Moreover, extension of the molecular insight regarding noncoding RNAs regulation 
of semaphorins and their receptor could improve even more the inhibition of angiogenesis if 
we take in consideration the ability of noncoding RNAs to regulate waste singling networks 
that involve more than one target gene.
Figure 5. Semaphorin receptors and ncRNAs regulation. Green – downregulated genes; Red – overexpressed genes.
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Semaphorin Regulatory 
miRNAs
Predicted targeting 
miRNAs
Role in lung cancer Potential clinical 
role in lung cancer
Ref.
Semaphorin 
3A (SEMA 3A)
miR‐30b miR‐95‐3p
miR‐589‐5p
NSCLC‐anticarcinogenic 
activity; low expression of 
SEMA 3A correlates with 
lymph node metastasis
Biomarker for 
prognosis
[104, 110]
Semaphorin 3B 
(SEMA 3B)
miR‐221 miR‐155‐5p
miR‐107
miR‐187‐5p
miR‐18a‐3p
miR‐708
miR‐3074‐5p
miR‐106b‐3p
miR‐340‐3p
miR‐3074‐5p
Cell proliferation and 
invasion
Small‐cell lung cancer‐
tumor suppressor role via 
induction of apoptosis and 
inhibition of angiogenesis
Marker for cancer 
progression
[111, 112]
Semaphorin 
3C (SEMA 3C)
– miR‐4746‐5p
miR‐500a‐5p
miR‐187‐5p
miR‐301a‐5p
miR‐21‐3p
miR‐106a‐3p
miR‐4677‐3p
miR‐3074‐5p
let‐7g‐3p
miR‐183‐3p
miR‐29a‐3p
miR‐519a‐5p
miR‐200c‐5p
miR‐4668‐3p
miR‐16‐2‐3p
miR‐193a‐3p
miR‐4326
miR‐4417
miR‐3664‐3p
miR‐155‐5p
miR‐590‐5p
miR‐616‐3p
miR‐3182
miR‐103a‐2‐5p
miR‐501‐5p
miR‐362‐3p
miR‐330‐5p
miR‐30e‐5p
A549 lung cancer 
cells ‐p65‐SEMA3C 
(cleaved SEMA3C) – 
protumorigenic activities
Novel 
antitumorigenic 
drug
[113]
Semaphorin 
3D (SEMA 3D)
– miR‐484
miR‐15b‐3p
miR‐16‐2‐3pmiR‐32‐3p
miR‐32‐5p
miR‐33a‐5p
miR‐33b‐3p
miR‐340‐5p 
miR‐4668‐3p
miR‐345‐5p
miR‐629‐5p
miR‐18a‐5p
miR‐1306‐5p
Proangiogenic and 
metastatic role
Prediction of 
response and 
survival
[114, 115]
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Semaphorin Regulatory 
miRNAs
Predicted targeting 
miRNAs
Role in lung cancer Potential clinical 
role in lung cancer
Ref.
let‐7a‐3p
miR‐183‐3p
miR‐21‐3p
miR‐21‐5p
miR‐4742‐5p
miR‐425‐5p
miR‐200a‐5p
miR‐301a‐5p
miR‐3619‐3p
miR‐589‐5p
miR‐3614‐3p
miR‐141‐5p
miR‐106a‐3p
miR‐93‐3p
Semaphorin 3E 
(SEMA 3E)
– miR‐340‐5p
miR‐1306‐5p
miR‐15b‐3p
let‐7d‐5p
miR‐1307‐3p
miR‐629‐5p
miR‐629‐3p
miR‐4677‐3p
let‐7g‐3p
miR‐301a‐5p
miR‐15b‐5p
miR‐19a‐3p
miR‐16‐2‐3p
miR‐105‐3p
miR‐18a‐5p
miR‐1306‐5p
miR‐19a‐3p
miR‐1307‐5p
miR‐505‐5p
In vivo promotion of lung 
metastasis and tumor 
progression
Possible target 
for therapeutic 
strategies
[116]
Semaphoring 
3F (SEMA 3F)
– miR‐29c‐3p
miR‐191‐3p
miR‐29b‐1‐5p
miR‐18a‐5p
miR‐20a‐5p
miR‐29b‐2‐5p
miR‐200c‐5p
let‐7g‐3p
let‐7a‐3p
let‐7d‐5p
miR‐7‐5p
miR‐3619‐3p
miR‐590‐5p
miR‐29b‐2‐5p
miR‐30e‐5p
miR‐676‐3p
miR‐135b‐3p
miR‐30c‐1‐3p
miR‐140‐3p
miR‐135b‐3p
miR‐140‐3p
Role in TGF‐beta1‐induced 
EMT
Antitumor role; 
Downregulated in lung 
cancer
Targets HIF‐1 and VEGF
Possible prognosis  
biomarker and 
therapeutic target
[117, 118]
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Semaphorin Regulatory 
miRNAs
Predicted targeting 
miRNAs
Role in lung cancer Potential clinical 
role in lung cancer
Ref.
Semaphorin 4B 
(SEMA 4B)
miR‐34 miR‐34 NSCLC—inhibition 
of invasion and 
growth—prevention of 
metastasis‐direct target of 
hypoxia‐inducible factor 
1 (HIF‐1)
miR‐34/p53 axis
Novel therapeutic 
target for 
inhibition of 
metastasis and 
growth
‐Novel therapeutic 
target through 
inhibition of HIF‐1
[119–121]
Semaphorin 
4C (SEMA 4C)
miR‐138 miR‐138 NSCLC‐cell proliferation 
and EMT
New target or 
prognosis marker 
for lung cancer 
treatment
[122]
Semaphorin 
4D (SEMA 4D)
miR‐214 miR‐199b‐3p
miR‐127‐3p
miR‐185‐5p
miR‐421
miR‐500a‐5p
miR‐22‐3p
miR‐500a‐5p
miR‐22‐3p
miR‐505‐5p
let‐7g‐3p
miR‐1269a
miR‐18a‐5p
miR‐3614‐3p
miR‐331‐3p
miR‐18a‐5p
miR‐18a‐3p
Highly expressed in lung 
cancer; promotion of 
angiogenesis; NSCLC‐in 
vitro inhibition of cell 
proliferation, migration, 
and invasion
Possible early 
prognosis tool and 
therapeutic target
[124–126]
Semaphorin 
5A (SEMA 5A)
- miR‐3677‐3p
miR‐3200‐3p
miR‐32‐5p
miR‐29b‐1‐5p
miR‐183‐3p
miR‐345‐5p
miR‐454‐5p
miR‐3614‐3p
miR‐18a‐3p
miR‐500a‐5p
miR‐106b‐3p
miR‐27b‐5p
let‐7g‐3p
miR‐660‐5p
miR‐135b‐3p
miR‐1306‐5p
miR‐29a‐3p
miR‐29b‐2‐5p
miR‐425‐3p
miR‐365a‐5p
miR‐3136‐3p
miR‐93‐3p
miR‐4787‐3p
miR‐19a‐3p
NSCLC‐tumor suppressor 
role; low levels associated 
with poor survival rate
New biomarker 
for NSCLC
[127]
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6. ncRNAs therapies targeting lung cancer angiogenesis
Once considered the “trash” of the genome, the noncoding RNA sequences are now emerg-
ing as important therapeutic targets (Table 7). Due to the complex regulatory network 
involving ncRNAs and also because of the personalized pathological expression pattern 
among cancer types, subtypes and malignant stages, ncRNAs are subjected to numerous 
preclinical studies regarding their silencing or induced expression [2]. A lipid‐based deliv-
ery vehicle for tumor suppressor miR‐34 was developed in order to enhance the expression 
of the specific molecule in a mouse model of non‐small‐cell lung cancer [132]. This approach 
has demonstrated to be efficient in both locally and systemically administration, being 
observed a reinforced miR expression concomitant with downregulation of the specific 
targets. Moreover, the intravenous delivery of miR‐34 mimic did not produce an immune 
reaction in mice, but unfortunately this was not the case in humans. Very recently, MRX34, 
the miR‐34 mimic, was stopped to be administrated in a cancer clinical trial due to major 
immune reactions [133].
Another therapeutic alternative that is currently on the scientific spotlight consist in the 
manipulation of the ciRNAs that can function as microRNA sponges, modulating their onco-
genic or tumor suppressor activity [136]. Despite the fact that there is a number of research 
studies focused on this type of noncoding RNAs, relatively little is known about the regulatory 
mechanism of circRNAs in cancer development. Future perspectives imply ciRNAs‐based 
therapy that can stand as “super‐sponges” and modulate the activity of extended regulatory 
miRNA networks, influencing at a superior level the carcinoma progression [136].
Semaphorin Regulatory 
miRNAs
Predicted targeting 
miRNAs
Role in lung cancer Potential clinical 
role in lung cancer
Ref.
Semaphorin 
6A (SEMA 6A)
miR‐27a/b miR‐1307‐3p
miR‐940
miR‐3187‐3p
miR‐33a‐5p
miR‐425‐3p
miR‐99b‐5p
miR‐99b‐3p
miR‐183‐3p
miR‐3176
miR‐760
miR‐345‐5p
miR‐4461
Endothelial cell repulsion New therapeutic 
target through 
manipulation 
of miR‐27a/b 
expression
[128, 129]
Semaphorin 
7A (SEMA 7A)
– 22_40957679_40957783 
(novel miRNA)
Promotion of tumor 
microenvironment and 
metastasis through 
regulation of prototypic 
chitinase‐like protein 
(Chi3l1)
Possible role as 
therapeutic target
[130]
Table 6. Semaphorin and the targeting miRNAs with implication in lung cancer.
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miRNAs Lung cancer 
subtype
Experimental model Therapeutic 
approach
Delivery 
system
Target gene Obtained results References
miR‐128 NSCLC NSCLC cells Ectopic miR‐128 
overexpression
VEGF‐C Inhibition of VEGF‐C expression concomitant 
with angiogenesis restriction
[53]
HUVECs and 
NSCLC cells
VEGF‐A, 
VEGFR‐2 and 
VEGFR‐3
Low expression of the target genes that are 
critical factors for angiogenesis
Nude mice (A549 
cells)
In vivo 
replacement 
therapy
Inhibition of lymphangiogenesis
miR‐497 NSCLC NSCLC cells Over expression 
of the miRNA
VEGF‐A Decreases in the levels of VEGF‐A protein 
with no significant changes for the VEGF‐A 
mRNA; inhibition of cell invasion
[123]
miRNA inhibition Increased levels of VEGF‐A protein with no 
significant changes for the VEGF‐A mRNA; 
increased cell invasion
NSCLC cells Ectopic 
expression of the 
miRNA sequence
HDGF Restoration of the miR‐497 levels reduced 
tumor development and angiogenesis in both 
in vitro and in vivo experimental models
[54]
SCID mouse 
xenograft model
miR‐378 NSCLC Swiss nude 
immunodeficient 
murine model 
(NCI‐H292‐Luc 
cells overexpressing 
miR‐378—
subcutaneous 
xenografts)
Overexpression 
of miR‐378
Lentiviral 
vectors 
particles 
(pEZX‐MR03 
backbone)
HMOX1 mir‐378 over expression models presented 
tumors with decreased vascularisation 
compared to the models with HMOX1 
induced over expression; increased oxygen 
partial pressure; increased MUC5AC, 
Ang‐1,MMP12 levels and decreased  TNF‐α 
and IL‐1β levels ‐ all essential genes for 
angiogenesis
[48]
miR‐126 A549, Y‐90 and SPC‐
A1 cells
Overexpression 
of miR‐126
mir-126 
expression 
vector 
(LV‐miR‐126)
VEGF‐A Dowregulation of VEGF‐A gene correlated 
with inhibited cell growth
[42]
Tumor xenograft 
model (A549 
infected with 
LV‐miR‐126)
mir-126 
expression vector 
(LV‐miR‐126)
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miRNAs Lung cancer 
subtype
Experimental model Therapeutic 
approach
Delivery 
system
Target gene Obtained results References
miR‐222 NSCLC H460 cells Inhibition 
of miR‐222 
expression
miR‐222 
inhibitor
p27 (in vivo over 
expression of 
p27 impaired 
angiogenesis)
Inhibition of oncogenic miR expression 
resulted in decreased cell viability and 
proliferation
[60, 61]
miR‐27b NSCLC HEK293 cells Cotransfection of 
miR‐27b mimics 
and WT Sp1 in 
order to express 
both miRNA and 
target gene
psiCHECK‐2 
vector
Sp1 Expression of miR‐27b resulted in 
suppression of cell growth and reduced 
invasion
[128]
miR‐130a NSCLC A549,CALU‐1, 
H1299 and A459 
cells
Transfection 
with miR‐130a in 
order to increase 
the endogenous 
levels of this 
sequence
pre‐miR 130a MET Strong reduction of MET (angiogenesis 
promoter) mRNA and protein levels; down 
regulation of miR‐221 and miR‐222, that are 
able to inhibit TIMP3 expression, molecule 
that in turn inhibits MET
[44]
miR‐210 Adenocarcinoma A549 cells Knocked down 
of miR‐210 
in hypoxic 
parameters
antimiR‐210 SDHD (positive‐
regulatory loop 
between miR‐210 
and HIF‐1α)
Decreased cell survival and alteration of 
mitochondrial phenotype
[63]
miR‐155 Adenocarcinoma A549 and H460 cells Inhibition of 
miR‐155 levels in 
cells preserved 
in hypoxic 
conditions
Synthetic 
antimiR‐155
FOXO3A 
(associated 
with roles in 
angiogenesis)
miR‐155 inhibition exercise a positive role 
through radiosensitization of the cells
[65, 134]
miR‐21 NSCLC A549 In vitro inhibition 
of miR‐21
miR‐21‐
sponge
PDCD4 
(associated with 
angiogenesis 
development)
Inhibition of miR‐21 ameliorates cell 
proliferation, migration, and invasion 
through PDCD4 modulation; knockdown of 
PDCD4 has been demonstrated to stimulate 
angiogenesis through positive regulation of 
Ang‐2 (negative prognostic factor in lung 
cancer)
[66, 135]
Table 7. Some relevant miRNAs tested on cell culture and animal models as potential therapeutic agents in lung cancer.
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The discovery of lncRNAs as regulators of cancer development has naturally conducted 
towards potential therapeutic alternatives using these long fragments as direct targets. The 
expression pattern of these sequences has been also investigated in lung cancer and the list 
of oncogenic and tumor suppressor pathological expressed lncRNAs is continuously grow-
ing. Administration of siRNA, shRNA, and miRNAs or antisense oligonucleotides in order 
to inhibit oncogenic lncRNAs is currently under investigation [137]. HOTAIR has been on the 
spotlight of artificial knockdown via siRNA delivery with great rates of success in lung cancer 
and also breast and pancreatic malignancies [100].
Moreover, the same approaches have been shown to be effective for the reverse of cisplatin 
resistance through reduced expression of p21 [138]. Downregulation of MALAT1 through 
shRNA delivery is also a potent therapeutic approach for lung cancer as it was shown 
reduced cell viability after this type of treatment [71]. MALAT1 has been also inhibited by 
exogenous antisense oligonucleotides, approach that induced reduced cancer progression 
through cell cycle arrest [151]. Considering that in lung cancer there are also downregulated 
tumor suppressor lncRNAs, the replacement therapy could also stand as an effective thera-
peutic approach for this type of carcinoma, but nonetheless the scientific information are quite 
limited regarding this area.
The discovery that miRNA sequences can act as key regulators in cancer pathways through 
aberrant expression has led to the idea that these fragments could serve as potent therapeutic 
targets [139]. In this sense, several strategies have been implemented until now: inhibition 
strategies—inhibitory antisense oligonucleotides and delivery vectors (miRNA sponges) and 
enhancement strategies—miRNA replacement therapy (Figure 6) [139, 140].
For the case of therapeutics that follow an antagonistic pattern, the activity of tumor promot-
ing miRNAs that are hazardous expressed is inhibited via administration of single stranded 
oligonucleotides complementary with the specific molecule or with the target binding site on 
the mRNA molecule; in either situation, the interaction between miRNAs and mRNA mol-
ecules is blocked and the downstream pathological pathway is strongly affected [140].
Delivery of anti‐miRNA oligonucleotides (AMOs) in the context of preclinical studies is still a 
problematic area considering the necessity of target administration, prolonged stability, and 
increased pharmacokinetic properties [140]. In this means, there is an urgent need for efficient 
delivery vectors/vehicles that are able to fulfill the reminded request in order to accomplish 
the treatment purpose. The majority of the freely administrated oligonucleotides is retrieved 
in the liver and kidneys and then eliminated through the urine. Also, the necessary dose of 
synthetic sequences is usually very high and the chance for off‐target delivery is also increas-
ing. Establishment of an effective delivery system will break the grounds of miRNAs thera-
peutics and also other noncoding treatment strategies [139]. The current strategy for in vivo 
administration implies conjugation‐based methods, where miRNA sequences are conjugated 
with different molecules like cholesterol [141] and α‐tocopherol [142]. Although these stud-
ies have demonstrated promising results, the efficiency of miRNA targeting is still limited. 
Another type of delivery method consists in liposome‐mediated delivery of siRNAs, where 
the first attempt [143] was to inhibit the replication of hepatitis B virus (HBV) in an animal 
model through administration of siRNAs integrated in as polyethylene glycol (PEG)–lipid 
conjugate (SNALP). Since then, different liposome‐based vehicles have been tested and the 
results are encouraging considering that the administration dose is significantly decreased 
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comparing to the naked oligonucleotides [144–147]. Progresses in the area of material science 
produced a promising in vivo delivery system in the form of polymer‐based nanoparticles 
that are more flexible than liposomes and also can be produced in a more homogenous man-
ner regarding their size and form [139]. In respect of siRNAs and anti‐miRs delivery, the 
size of the vehicle is very important in order to permit the passing through cellular com-
partments, where nanoparticles can fulfill this request having a size between 10 and 100 nm 
[139]. Moreover, in order to avoid the stimulation of the immune system, cyclodextrin–PEG 
conjugated nanoparticles have been developed and tested for the inhibition of EWS–FLI1 in 
an in vivo model of Ewing's sarcoma [148]. Attracting strategies for targeted therapies consist 
in the conjugation of siRNAs or anti‐miR sequences with specific antibodies able to conduct 
the small fragments towards distinctive cells expressing the desired antigen [147, 149, 150].
Figure 6. MicroRNAs have emerged as important regulators of lung cancer angiogenesis and also as key therapeutic 
targets regarding inhibition or enhancement strategies. MiRNAs sequences that are marked with green composed the 
tumor suppressor group that have been tested in the context of replacement therapies; the genes marked with the same 
color represent the target genes that have been downregulated after therapeutic modulation of miRNAs. Inversely, 
miRNAs sequences marked with red are oncogenic ones proposed for inhibition in what regards antiangiogenic 
programs; the genes marked with the same color also represent the target genes, but in this case their expression has 
been augmented.
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MiRNA replacement therapy is more limited regarding the current attempts and results, 
although it seems to emerge as a more efficient form of treatment considering that the majority 
of pathological expressed miRNAs consist in downregulated or inhibited tumor suppressor 
sequences [140]. Even if the success of this therapeutic strategy could be greater than miRNA 
inhibition workflows, the requirements for the structure and composition of the replacement 
fragment are much more stringent considering the necessity of RISC uptake. Furthermore, the 
impediments regarding the delivery system for these oligonucleotides are the same as in the 
case of inhibitory antisense attempts.
7. Conclusions and future perspectives
Lung cancer remains the most deadly disease from the oncological field, being an aggressive 
form of cancer that is usually diagnosed in late stages with minimal therapeutic alternatives. 
Even in the case of early discovery, the classical treatments have failed numerous times due 
to compensatory mechanisms developed within the tumor environment leading to the same 
negative outcome. Therefore, we face a crisis situation where we need to develop new thera-
peutic tools for lung cancer management able to target key elements/pathways, but avoid 
in the same time the possibility of alternative carcinogenic pathways activation. One of the 
hallmarks of cancer is represented by angiogenesis, process that is in the sight of research-
ers for some time, but the classical inhibition of central molecules like VEGF has failed to 
deliver long‐lasting results. Therefore, ncRNAs have emerged as potential lifesaving agents 
due to the capacity of extensive modulation, where the same ncRNA is able to target multiple 
genes and regulate their function. Also the same microRNA, or more recently discovered, the 
lncRNA can be encounter in different consecutive processes in pulmonary carcinogenesis, 
as in the case of hypoxia and angiogenesis. Development of novel therapeutic tools able to 
transform the pathological expression of ncRNAs, mainly through silencing of upregulated 
patterns, will enable a more extensive, and in the same time, specific approach that will prob-
ably excludes the installation of compensatory mechanism and significantly contribute to a 
better outcome in lung cancer patients. The concept of noncoding RNAs as therapeutic tar-
gets in the clinical context is now more feasible than ever, being supported by numerous 
preclinical studies. One of the main approaches should involve manipulation of miRNAs 
that are actively implicated in the regulation of VEGF genes expression, genes that hold a 
key role in the vascular development process. Even more, a heterogeneous approach that 
implies the administration of different miRNA sequences able to target multiple genes and 
naturally multiple pathological pathways within the angiogenic process will represent a more 
extended form of therapy that could modify extensive regulatory networks. This type of tar-
geting will also minimize the compensatory mechanisms that are usually encountered after 
the implementation of classical therapeutic strategies due to concomitant regulation of mul-
tiple signaling pathways. Additionally, some other approaches may be used for the inhibi-
tion of angiogenesis. For example, semaphorins are now emerging as important regulators of 
vascular density in malignancies, with possible roles as prognostic tools or even therapeutic 
targets. Inhibition of procarcinogenic semaphorins would represent a novel course of action 
regarding cancer treatment considering their central role in vascular density. Moreover, the 
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receptors associated with semaphorins contain binding sites for both semaphorins and VEGF 
molecules, engaging the competitive binding between these types of molecules. Managing 
the expression of VEGF via miRNA therapy concomitant with the levels of neuropilins (sema-
phorins receptors) will enable a more dramatic approach that could have more drastic results 
for cancer development.
Current therapeutic programs are promoting the effectiveness of specific sequence inhibition 
or enhancement through administration of antisense oligonucleotides or supplementation of 
the same sequence through exogenous enhancement. Development of chemically modified 
oligonucleotides under the form of medication for individuals diagnosed with cancer is now 
at the close horizon. Administration of synthetic oligonucleotides for noncoding RNAs inhi-
bition or upregulation will enhance the effect of the current therapeutic strategies by modu-
lation of specific gene expression able to influence the carcinogenic process or even reverse 
the malignant installation. In this sense, it is now clearly understood that the major strat-
egy towards cancer treatment is focused on taking advantage of the key roles of noncoding 
sequences regarding the modulation of entire aberrant regulatory networks through manipu-
lation of central molecules.
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